By Clinical Informatics News Staff

March 18, 2015 | Clinical Ink has merged with CentrosHealth, joining Clinical Ink’s eSource solutions with CentrosHealth’s mobile apps for clinical trial patient engagement and electronic patient reported outcomes (ePRO). The merger brings MPM Capital and F2 Ventures to Clinical Ink’s list of existing investors.

Clinical Ink also announced a strategic partnership with Novartis Pharmaceuticals, as part of their Trials of the Future initiative, to help drive industry-wide adoption of fully electronic clinical trials. 

“The combination of Clinical Ink and CentrosHealth backed by the deep expertise, relationships, and financial resources of MPM Capital creates a powerful opportunity to transform the clinical development business model,” said Ed Seguine, CEO of Clinical Ink, in a press release.  “This multi-part transaction underscores the tremendous progress we’ve made and the future potential for our combined businesses to deliver innovative technology solutions that eliminate the root causes of clinical trial inefficiency.  The involvement of Novartis is a significant validation of our pioneering efforts to create a completely paperless clinical trial platform and to reduce the cost, time and complexity of clinical research.”

By using CentrosHealth and SureSource, Clinical Ink’s award-winning purpose-built eSource platform for research sites, research sponsors can receive all of their data, both from the site and the patient, in real-time and can dramatically reduce the cost, time, and complexity of the clinical trial process.

“The CentrosHealth approach to patient engagement is based on the simple premise that patients want to actively manage their participation in clinical research,” said Jeremy Sohn, Founder/CEO of CentrosHealth.  “Our platform seamlessly integrates clinical trial activities such as medication reminders, visit scheduling, activity measurements and ePRO into patients’ every-day life through personalized notifications, text messages, calendar integration, and a highly functional mobile application on their personal cellphone.”

As a result of this transaction representatives from MPM Capital and F2 Ventures will join the existing board of directors of Clinical Ink.